Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascorbate and gemcitabine in pancreatic cancer
NCT01515046Phase 2Terminated
- Sponsor
- Joseph J. Cullen
- Start
- Sep 2012
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ascorbic acid in pancreatic adenocarcinoma (PDAC), sponsored by Joseph J. Cullen. Primary endpoint: Overall Survival at 5 years. Started Sep 2012; status: terminated.
02
Drugs
ascorbic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01515046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01515046.